Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities

Sci Rep. 2017 Jul 24;7(1):6340. doi: 10.1038/s41598-017-06955-w.

Abstract

Drug incompatibilities are considered as one of the most critical problems in intensive care units. In the current study, the ability of nanomaterials to prevent drug incompatibilities in clinical settings has been investigated. As a proof-of-concept, the ability of niosomes to prevent physical and chemical incompatibilities that occur upon mixing acyclovir and vancomycin during management of acute meningitis has been explored. Nanosized spherical particles loaded separately with either vancomycin or acyclovir, with high entrapment efficiency (ca. 46-56%), could be prepared, and sustained release of their entrapped cargoes have been demonstrated over time. We have shown that precipitation, degradation and loss of biological activity of drugs occurred upon mixing solutions of the free drugs. On the contrary, drugs loaded separately inside niosomal structures exhibited high stability, exceptional physical and chemical compatibilities for up to 48 h with complete preservation of the antimicrobial activity of vancomycin. This study opens a venue for a new spectrum of applications of nanomaterials in preventing clinically significant drug incompatibilities, aiming at the reduction of adverse reactions, cost and hospitalization period, and improvement of patient compliance and therapeutic outcomes.

MeSH terms

  • Acyclovir / chemistry*
  • Acyclovir / therapeutic use
  • Chemical Precipitation
  • Delayed-Action Preparations
  • Drug Carriers / chemistry
  • Drug Incompatibility
  • Drug Stability
  • Humans
  • Intensive Care Units
  • Liposomes / chemistry*
  • Meningitis / drug therapy*
  • Nanotechnology
  • Particle Size
  • Vancomycin / chemistry*
  • Vancomycin / therapeutic use

Substances

  • Delayed-Action Preparations
  • Drug Carriers
  • Liposomes
  • Vancomycin
  • Acyclovir